From: The effect of recombinant versus plasma-derived von Willebrand factor on prolonged PFA closure times in ECMO patients with acquired von Willebrand syndrome – an observational study
Patient
Diagnosis
VWF activity (IU/dl)
VWF antigen (IU/dl)
VWF Activity/Antigen ratio
1
VWS type 1
42
39
0.93
2
VWS type 1 (Vicenza)
10
3
VWS type 2A (2C Miami)
166
14
0.08